Novartis AG (SWX:NOVN) agreed to acquire Calypso Biotech B.V. for $425 million on January 8, 2024. Calypso?s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development milestones of up to $175 million. Lazard B.V. acted as financial advisor and Goodwin Procter LLP acted as legal advisor to Calypso Biotech B.V.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99.06 CHF | +0.16% | +0.77% | +16.72% |
07:00am | Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance | DJ |
Jul. 15 | Brace for a flurry of speeches from Fed officials |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.72% | 228B | |
+55.35% | 815B | |
+31.64% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+15.51% | 247B | |
+16.54% | 180B | |
+4.31% | 170B | |
+2.52% | 126B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis AG agreed to acquire Calypso Biotech B.V. for $425 million.